Attached files

file filename
EX-32.A - EXHIBIT 32.A - BRISTOL MYERS SQUIBB CObmyex32a_20210630.htm
EX-31.B - EXHIBIT 31.B - BRISTOL MYERS SQUIBB CObmyex31b_20210630.htm
EX-31.A - EXHIBIT 31.A - BRISTOL MYERS SQUIBB CObmyex31a_20210630.htm
EX-10.I - AMENDMENT TO REVOLVING CREDIT FACILITY DATED JULY 30, 2012 - BRISTOL MYERS SQUIBB CObmyex10i20210630.htm
EX-10.H - EXTENSION NOTICE FOR REVOLVING CREDIT FACILITY AGREEMENT DATED JULY 30, 2012 - BRISTOL MYERS SQUIBB CObmyex10h20210630.htm
EX-10.G - AMENDMENT AND WAIVER TO REVOLVING CREDIT FACILITY DATED SEPTEMBER 29, 2011 - BRISTOL MYERS SQUIBB CObmyex10g20210620.htm
EX-10.F - EXTENSION NOTICE FOR REVOLVING CREDIT FACILITY DATED SEPTEMBER 29, 2011 - BRISTOL MYERS SQUIBB CObmyex10f20210630.htm
10-Q - 10-Q - BRISTOL MYERS SQUIBB CObmy-20210630.htm

EXHIBIT 32b
Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the "Report"), as filed with the Securities and Exchange Commission on July 28, 2021, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.

 
/s/ David V. Elkins
David V. Elkins
Chief Financial Officer
July 28, 2021
 

This written statement is being furnished to the Securities and Exchange Commission as an exhibit to the Report. A signed original of this written statement required by Section 906 has been provided to Bristol-Myers Squibb Company and will be retained by Bristol-Myers Squibb Company and furnished to the Securities and Exchange Commission or its staff upon request.